Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
featured
A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

  • 270 views
  • 08 Nov, 2020
  • 1 location
Dapagliflozin and Hepatic Glucose Metabolism

the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake

  • 0 views
  • 24 Jan, 2021
  • 1 location
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

A real-world, nationwide, register-based, randomised trial (RRCT) comparing SGLT2 inhibitors with metformin as standard treatment in early typ 2 diabetes. An open-label trial addressing efficacy with respect to clinically important macro- and microvascular events.

sglt2
metformin
dapagliflozin
sglt2 inhibitor
  • 22 views
  • 24 Jan, 2021
  • 1 location
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.

metformin
saxagliptin
impaired glucose tolerance
prediabetic state
fasting
  • 32 views
  • 25 Jan, 2021
  • 1 location
Effect of Pioglitazone on T2DM Patients With COVID-19

Approximately 10-15% of patients infected with COVID-19 develop severe illness characterized by respiratory distress, increased risk of clotting disease, myocardial damage, stroke and mortality. Subjects with Type 2 diabetes (T2DM) are at increased risk for severe COVID-19 disease. Exuberant inflammatory and immune responses were suggested as the etiology responsible for …

  • 0 views
  • 25 Mar, 2021
  • 5 locations
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Background The drug Jardiance treats diabetes. It lowers blood sugar by increasing glucose the kidneys excrete. This increases levels of ketones formed in the blood. The body makes ketones when it does not have enough glucose for fuel. The brains of many people with age-related diseases like Alzheimer s do …

  • 84 views
  • 26 Jan, 2021
  • 1 location
Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

Patients with diabetes have poorer cardiac surgery outcomes compared with non-diabetics. Proper blood glucose management is critical to reduce the morbidity and mortality for diabetic patients after cardiac surgery. SGLT2 inhibitors including dapagliflozin as a new diabetes drug can reduce heart failure hospitalization rates and overall cardiovascular mortality in patients …

thoracotomy
sglt2 inhibitor
diabetes
sglt2
dapagliflozin
  • 0 views
  • 24 Jan, 2021
  • 1 location
Effect of Empagliflozin on Body Composition and Ketones

The purpose of this study is to evaluate changes of body composition induced by Sodium-glucose cotransporter-2 (SGLT2) inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).

type 2 diabetes mellitus
oral hypoglycemic
hypoglycemic agents
  • 3 views
  • 04 Apr, 2021
  • 1 location
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

in detectable amounts in the urine) with an SGLT2 inhibitor, dapagliflozin.

sulfonylurea
metformin
sglt2 inhibitor
electrocardiogram
sglt2
  • 49 views
  • 25 Jan, 2021
  • 1 location
Effect of Ertugliflozin on Cardiac Function in Diabetes

The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2 inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using

  • 0 views
  • 05 Apr, 2021
  • 1 location